The success of Sildenafil initially drove a period of growth for the drug industry, but recent shifts present a complicated picture for investors. Off-patent versions are eating into profits, and persistent legal https://arunlkgp160044.myparisblog.com/41726801/the-blue-pill-and-pharma-a-precarious-play